Janus Henderson Investors: Investment Portfolio & Startup News
Janus Henderson Investors
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
OMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
OMass Therapeutics is a biotechnology company developing small molecule therapeutics against highly validated target ecosystems in endocrinology and immunology. OMass Therapeutics develops OMS1620 for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome and advances an SLC15A4 inhibitor for lupus and related diseases.
Tenpoint Therapeutics unlocks a £170m Series B from investors to rejuvenate vision in the aging eye
Tenpoint Therapeutics develops treatments for age-related eye conditions. Its products are designed to address presbyopia and other vision issues through clinically developed ophthalmic therapies.
Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics
Artios Pharma develops cancer treatments that target DNA damage response pathways, focusing on patient groups with limited existing treatment options.
More venture news
- 15 Oct 2026
OMass TherapeuticsOMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
Series CLife Sciences - 30 Sept 2026
MetaviewMetaview unlocks a £45m Series C led by Insight Partners to automate hiring with sourcing and screening agents
Series CHR - 23 Sept 2026
Basecamp ResearchBasecamp Research unlocks £105m Series C led by S32 to design medicines with frontier AI models
Series CLife Sciences
